help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Published ahead of print on June 19, 2003, doi:10.1164/rccm.200209-982OC

Am. J. Respir. Crit. Care Med., Volume 168, Number 9, November 2003, 1075-1083

A more recent version of this article appeared on November 1, 2003
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
200209-982OCv1
168/9/1075    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nakamura, H.
Right arrow Articles by Hoshino, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakamura, H.
Right arrow Articles by Hoshino, T.

Submitted on September 5, 2002
Accepted on June 16, 2003

Redox-Active Protein Thioredoxin Prevents Proinflammatory Cytokine- or Bleomycin-Induced Lung Injury

Hajime Nakamura1, Masaki Okamoto2, Seiya Kato3, Shinichi Araya1, Kotaro Oizumi2, Howard A Young4, Hisamichi Aizawa2, Junji Yodoi1, Keiko Nomiyama2, and Tomoaki Hoshino2*

1 Biological Responses, Institute for Virus Research, Kyoto University, Kyoto, Kyoto, Japan, 2 Internal Medicine 1, Kurume University, Kurume, Fukuoka, Japan, 3 Pathology, Kurume University, Kurume, Fukuoka, Japan, 4 Laboratory of Experimental Immunology, DBS, National Cancer Institute at Frederick, Frederick, MD, USA

* To whom correspondence should be addressed. E-mail: hoshino{at}med.kurume-u.ac.jp.

Thioredoxin (TRX) is a multifunctional redox (reduction/oxidation)-active protein that scavenges reactive oxygen species by itself or together with TRX-dependent peroxiredoxin. TRX also has chemotaxis-modulating functions and suppresses leukocyte infiltration into sites of inflammation. Leukocyte infiltration and oxidative stress may be involved in the pathogenesis of several diseases, including interstitial lung diseases (ILD). We examined the effects of TRX in two mouse models of human ILD. Recently, we established a new mouse model for human ILD in which daily administration of proinflammatory cytokine IL-18 with IL-2 induces lethal lung injury accompanied by acute interstitial inflammatory responses. Administration of recombinant TRX suppressed IL-18/IL-2-induced interstitial infiltration of cells and prevented death and lung tissue damage. TRX-transgenic mice also showed resistance to lethal lung injury caused by IL-18/IL-2. Administration of bleomycin induces the infiltration of polymorphonuclear and mononuclear leukocytes in the pulmonary interstitium, followed by progressive fibrosis. Wild type mice given recombinant TRX treatment and TRX-transgenic mice demonstrated a decrease in bleomycin-induced cellular infiltrates and fibrotic changes in the lung tissue. These results suggest TRX modulates pulmonary inflammatory responses and acts to prevent lung injury. TRX may have clinical benefits in human ILD, including lung fibrosis, for which no effective therapeutic strategy currently exists.
Key words: thioredoxin (TRX), redox, interstitial lung diseases, cytokine, bleomycin




This article has been cited by other articles:


Home page
 Am. J. Respir. Cell Mol. Bio.Home page
T. Hoshino, M. Okamoto, Y. Sakazaki, S. Kato, H. A. Young, and H. Aizawa
Role of Proinflammatory Cytokines IL-18 and IL-1{beta} in Bleomycin-Induced Lung Injury in Humans and Mice
Am. J. Respir. Cell Mol. Biol., December 1, 2009; 41(6): 661 - 670.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
Y. Inomata, H. Tanihara, M. Tanito, H. Okuyama, Y. Hoshino, T. Kinumi, T. Kawaji, N. Kondo, J. Yodoi, and H. Nakamura
Suppression of Choroidal Neovascularization by Thioredoxin-1 via Interaction with Complement Factor H
Invest. Ophthalmol. Vis. Sci., November 1, 2008; 49(11): 5118 - 5125.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
A. R. Hemnes, A. Zaiman, and H. C. Champion
PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation
Am J Physiol Lung Cell Mol Physiol, January 1, 2008; 294(1): L24 - L33.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
T. E. Tipple, S. E. Welty, L. K. Rogers, T. N. Hansen, Y.-E. Choi, J. P. Kehrer, and C. V. Smith
Thioredoxin-Related Mechanisms in Hyperoxic Lung Injury in Mice
Am. J. Respir. Cell Mol. Biol., October 1, 2007; 37(4): 405 - 413.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
T. Hoshino, S. Kato, N. Oka, H. Imaoka, T. Kinoshita, S. Takei, Y. Kitasato, T. Kawayama, T. Imaizumi, K. Yamada, et al.
Pulmonary Inflammation and Emphysema: Role of the Cytokines IL-18 and IL-13
Am. J. Respir. Crit. Care Med., July 1, 2007; 176(1): 49 - 62.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
S. Ohashi, A. Nishio, H. Nakamura, M. Kido, S. Ueno, N. Uza, S. Inoue, H. Kitamura, K. Kiriya, M. Asada, et al.
Protective roles of redox-active protein thioredoxin-1 for severe acute pancreatitis
Am J Physiol Gastrointest Liver Physiol, April 1, 2006; 290(4): G772 - G781.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. GenomicsHome page
D. Zieker, E. Fehrenbach, J. Dietzsch, J. Fliegner, M. Waidmann, K. Nieselt, P. Gebicke-Haerter, R. Spanagel, P. Simon, A. M. Niess, et al.
cDNA microarray analysis reveals novel candidate genes expressed in human peripheral blood following exhaustive exercise
Physiol Genomics, November 17, 2005; 23(3): 287 - 294.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
W. E. Lawson, V. V. Polosukhin, O. Zoia, G. T. Stathopoulos, W. Han, D. Plieth, J. E. Loyd, E. G. Neilson, and T. S. Blackwell
Characterization of Fibroblast-specific Protein 1 in Pulmonary Fibrosis
Am. J. Respir. Crit. Care Med., April 15, 2005; 171(8): 899 - 907.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. Tobin
Tuberculosis, Lung Infections, Interstitial Lung Disease, Social Issues and Journalology in AJRCCM 2003
Am. J. Respir. Crit. Care Med., January 15, 2004; 169(2): 288 - 300.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. D. Crapo
Redox Active Agents in Inflammatory Lung Injury
Am. J. Respir. Crit. Care Med., November 1, 2003; 168(9): 1027 - 1028.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2003 American Thoracic Society 		  ATS Quiz on Sleep Study Tracings